# US 2026/0191927 A1 · Formulation of therapeutic agents for improved permeation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0191927 A1
- Document ID: US20260191927A1
- Status: Published application
- Kind: A1
- Application number: 19/368,009
- Filed: 2025-10-24
- Published: 2026-07-09
- Earliest claimed: 2023-04-26
- Assignees: Vivtex Corporation
- Applicants: Vivtex Corporation
- Inventors: Thomas VON ERLACH; James L. WRIGHT; Edgardo RIVERA-DELGADO
- Web page: https://patentgrep.com/patent/US20260191927A1

## CPC

- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/23: Calcitonins
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides compositions and methods for enhanced delivery of a therapeutic agent to a subject, wherein the composition comprises the therapeutic agent, at least one bile acid or salt thereof, and optionally one or more co-excipients.

## Claims

### Claim 1

A composition comprising
(i) a compound selected from the group consisting of: (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS); and
(ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amount of the at least one bile acid or salt thereof is effective to increase gastrointestinal (GI) permeability of the compound relative to GI permeability of the compound alone.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the polypeptide has a molecular weight greater than about 1 kDa, about 2 kDa, about 3 kDa, about 4 kDa, about 5 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, or about 30 kDa.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The composition of claim 1, wherein the polypeptide is an enzyme, an antibody or antigen binding fragment thereof, an antibacterial agent, a hormone, a growth factor, a chemokine, a cell signaling factor, or a cytokine.

### Claim at position 6

-10. (canceled)

### Claim 11 (depends on 1)

The composition of claim 1, wherein the nucleic acid comprises ribonucleosides, deoxyribonucleosides, or a combination thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the nucleic acid is an immunostimulatory oligonucleotide, an mRNA, a plasmid DNA, or an RNA interference oligonucleotide.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the RNA interference oligonucleotide is an siRNA, a shRNA, a miRNA, or an antisense oligonucleotide.

### Claim at position 10

-21. (canceled)

### Claim 22 (depends on 1)

The composition of claim 1, wherein the class III or class IV compound has a molecular weight greater than about 1 kDa, about 2 kDa, about 3 kDa, about 4 kDa, about 5 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, or about 30 kDa.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The composition of claim 1, wherein the compound is a polypeptide, a nucleic acid, an oligosaccharide, a small molecule, a lipid, or a combination thereof.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the effective concentration of the at least one bile acid or salt thereof is at least about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold greater than the CMC.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the effective concentration of the at least one bile acid or salt thereof is about 2-fold to about 200-fold greater than the CMC.

### Claim 27 (depends on 1)

The composition of claim 1, wherein the effective concentration of the at least one bile acid or salt thereof is about 32 mg/mL to about 160 mg/mL.

### Claim at position 17

-37. (canceled)

### Claim 38 (depends on 1)

The composition of claim 1, wherein the at least one bile acid or salt thereof is selected from the group consisting of sodium taurocholate (STC), sodium glycocholate (GCA), sodium cholate (CHA), 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), sodium taurodeoxycholate (TDCA), sodium glycodeoxycholate (GDCA), sodium deoxycholate (DCA), sodium taurochenodeoxycholate (TCDCA), sodium glycochenodeoxycholate (GCDCA), and sodium chenodeoxycholate (CDCA).

### Claim 39 (depends on 1)

The composition of claim 1, wherein the bile acid or salt thereof has a CMC of less than about 30 mg/mL, about 20 mg/mL, about 15 mg/mL, or about 5 mg/mL.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

The composition of claim 1, wherein the amount (mg) of the at least one bile acid or salt thereof is substantially equivalent to the effective concentration (mg/mL) multiplied by a dilution factor (mL) of about 2 mL to about 30 mL.

### Claim at position 22

42-44. (canceled)

### Claim 45 (depends on 1)

The composition of claim 1, wherein the amount of the at least one bile acid or salt thereof is about 60 mg to about 1,200 mg.

### Claim at position 24

-109. (canceled)

### Claim 110

A dosage form comprising a composition comprising
(i) a compound selected from the group consisting of: (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS); and
(ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt.

### Claim 111 (depends on 110)

The dosage form of claim 110, wherein the amount of the at least one bile acid or salt thereof is sufficient to achieve the effective concentration at a site of absorption in the GI tract.

### Claim 112 (depends on 110)

The dosage form of claim 110, wherein the dosage form is a solid dosage form or a liquid dosage form.

### Claim 113

(canceled)

### Claim 114 (depends on 1)

The dosage form of claim 1_12, wherein the solid dosage form is formulated for immediate release or delayed release.

### Claim at position 30

-124. (canceled)

### Claim 125

A method of enhancing gastrointestinal (GI) permeability of a compound, the method comprising administering a composition comprising
(i) a compound selected from the group consisting of: (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS); and
(ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt.

### Claim at position 32

126-127. (canceled)

### Claim 128 (depends on 125)

The method of claim 125, wherein the administering is enteral, rectal, intraduodenal, or oral.

### Claim at position 34

-131. (canceled)

### Claim 132 (depends on 125)

The method of claim 125, wherein the GI permeability of the compound is increased relative to GI permeability of a control composition.

### Claim at position 36

133-134. (canceled)

### Claim 135 (depends on 125)

The method of claim 125, wherein GI permeability is measured in vivo or in vitro using a transwell permeability assay, a Ussing chamber assay, or a GI Tract-Organ Robotic Interface System (GI-ORIS)-based permeability assay.

### Claim 136 (depends on 110)

A method of increasing bioavailability of a compound in a subject, the method comprising administering the dosage form of claim 110 to the GI tract of the subject, wherein the dosage form comprises an effective dose of the compound.

### Claim 137 (depends on 136)

The method of claim 136, wherein the bioavailability of the compound is increased relative to bioavailability of a control composition.

### Claim at position 40

-150. (canceled)

### Claim 151

A kit comprising a container comprising a composition or a dosage form comprising
(i) a compound selected from the group consisting of: (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS):
(ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt; and
(iii) a package insert comprising instructions for administering the composition for increasing bioavailability of the compound in a subject from the GI tract.

### Claim at position 42

-154. (canceled)
